Conversely, in patients with CCD and LVEF > 40%, the use of an SGLT2 inhibitor can be beneficial in decreasing HF hospitalizations and to improve QOL irrespective of diabetes status (COR2a).7 The gene discussed is SLC5A2; the disease is diabetes mellitus.